Education
About Us
Working with TipRanks
Follow Us
Lexeo Therapeutics, Inc. (LXEO)
NASDAQ:LXEO
RESEARCH TOOLSreports
Total Valuation
Lexeo Therapeutics, Inc. has a market cap or net worth of $130.13M. The enterprise value is $184.07M.
Market Cap$130.13M
Enterprise Value$184.07M
Share Statistics
Lexeo Therapeutics, Inc. has 33,197,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding33,197,000
Owned by Insiders1.65%
Owned by Institutions38.97%
Financial Efficiency
Lexeo Therapeutics, Inc.’s return on equity (ROE) is -0.84 and return on invested capital (ROIC) is -83.43%.
Return on Equity (ROE)-0.84
Return on Assets (ROA)-0.67
Return on Invested Capital (ROIC)-83.43%
Return on Capital Employed (ROCE)-0.85
Revenue Per Employee0.00
Profits Per Employee-1.31M
Employee Count75
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Lexeo Therapeutics, Inc. is -2.13. Lexeo Therapeutics, Inc.’s PEG ratio is -0.24.
PE Ratio-2.13
PS Ratio0.00
PB Ratio-2.19
Price to Fair Value1.79
Price to FCF-4.47
Price to Operating Cash Flow-4.54
PEG Ratio-0.24
Income Statement
In the last 12 months, Lexeo Therapeutics, Inc. had revenue of 0.00 and earned -98.33M in profits. Earnings per share was -3.09.
Revenue0.00
Gross Profit0.00
Operating Income-105.77M
Pretax Income-98.33M
Net Income-98.33M
EBITDA-96.22M
Earnings Per Share (EPS)-3.09
Cash Flow
In the last 12 months, operating cash flow was -88.00M and capital expenditures -275.00K, giving a free cash flow of -88.28M billion.
Operating Cash Flow-88.00M
Free Cash Flow-88.28M
Free Cash Flow per Share-2.66
Dividends & Yields
Lexeo Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.39
52-Week Price Change-74.94%
50-Day Moving Average3.20
200-Day Moving Average5.82
Relative Strength Index (RSI)57.15
Average Volume (3m)871.82K
Important Dates
Lexeo Therapeutics, Inc. upcoming earnings date is Aug 18, 2025, TBA Not Confirmed.
Last Earnings DateMay 12, 2025
Next Earnings DateAug 18, 2025
Ex-Dividend Date―
Financial Position
Lexeo Therapeutics, Inc. as a current ratio of 5.52, with Debt / Equity ratio of -11.94%
Current Ratio5.52
Quick Ratio5.52
Debt to Market Cap0.00
Net Debt to EBITDA0.26
Interest Coverage Ratio-927.77
Taxes
In the past 12 months, Lexeo Therapeutics, Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Lexeo Therapeutics, Inc. EV to EBITDA ratio is -1.91, with an EV/FCF ratio of -2.25.
EV to Sales0.00
EV to EBITDA-1.91
EV to Free Cash Flow-2.25
EV to Operating Cash Flow-2.27
Balance Sheet
Lexeo Therapeutics, Inc. has $99.83M in cash and marketable securities with $9.40M in debt, giving a net cash position of -$90.43M billion.
Cash & Marketable Securities$99.83M
Total Debt$9.40M
Net Cash-$90.43M
Net Cash Per Share-$2.72
Tangible Book Value Per Share$3.68
Margins
Gross margin is -75.08%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-75.08%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Lexeo Therapeutics, Inc. is $16.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$16.25
Price Target Upside314.54% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast-24.18%